This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Jack Hirsh, MD, FRCP(C), FRACP

Arch Intern Med. 1981;141(3):311-315.

Abstract
• Four antiplatelet drugs have been evaluated in cerebrovascular disease and in coronary heart disease—dipyridamole, clofibrate, sulfinpyrazone, and aspirin. There is no evidence that dipyridamole or clofibrate is beneficial in patients with stroke or myocardial infarction. Aspirin is effective in reducing stroke and death in patients with transient cerebral ischemia. Although aspirin has not been reported to significantly (statistically) reduce mortality or frequency of ischemic events in patients with acute myocardial infarction, five of six randomized trials showed a similar favorable trend. Sulfinpyrazone seems to be ineffective in the treatment of transient cerebral ischemia, but there is evidence that it decreases the incidence of sudden death in patients with myocardial infarction. In patients with prosthetic heart valves, the combined use of aspirin or dipyridamole with an oral anticoagulant is more effective in preventing systemic embolism than an oral anticoagulant alone.

(Arch Intern Med 1981;141:311-315)

Author Affiliations
From the Departments of Pathology and Medicine, McMaster University, Hamilton, Ontario, Canada.

Footnotes
Reprint requests to the Department of Pathology, McMaster University Medical Center, Hamilton, Ontario, Canada (Dr Hirsh).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Underlying Problems Resulting in Controversies in the Clinical Management of Transient Ischemic Attacks: An Overview
Slade et al.
ANGIOLOGY 1983;34:639-645.
ABSTRACT